INCHEON, Korea--(BUSINESS WIRE)--Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion ...

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments ...

The P.1 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) was first identified in Brazil and has since spread around the world, demonstrating increased ...

Regdanvimab (CT-P59) (40mg/kg) achieved statistically significant and clinically meaningful results in four main endpoints including primary and three key secondary endpoints; the company anticipates ...

Regdanvimab (CT-P59) (40mg/kg) achieved statistically significant and clinically meaningful results in four main endpoints including primary and three key secondary endpoints; the company anticipates ...